OTCMKTS:FSNUY

Fresenius SE & Co. KGaA - FSNUY Stock Forecast, Price & News

$5.35

+0.02 (+0.38%)

(As of 09/26/2022 12:00 AM ET)

Add

Compare

Today's Range: $5.25
▼
$5.40
50-Day Range: $5.33
▼
$7.20
52-Week Range: $5.25
▼
$12.27

Volume: 297,022 shs
Average Volume: 297,438 shs
Market Capitalization: $12.05 billion

P/E Ratio: 6.15
Dividend Yield: 3.04%
Price Target: $46.82

Fresenius SE & Co. KGaA MarketRank™ Forecast

Analyst Rating: Hold
2.44 Rating Score
Upside/Downside: 775.2% Upside
$46.82 Price Target
Short Interest: Healthy
0.01% of Shares Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: 21.88%
From $0.96 to $1.17 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.83 out of 5 stars

3.2

Analyst's Opinion

Consensus Rating
Fresenius SE & Co. KGaA has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 4 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $46.82, Fresenius SE & Co. KGaA has a forecasted upside of 775.2% from its current price of $5.35.
Amount of Analyst Coverage
Fresenius SE & Co. KGaA has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
0.01% of the outstanding shares of Fresenius SE & Co. KGaA have been sold short.
Short Interest Ratio / Days to Cover
Fresenius SE & Co. KGaA has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Fresenius SE & Co. KGaA has recently increased by 642.70%, indicating that investor sentiment is decreasing significantly.

2.5

Dividend Strength

Dividend Yield
Fresenius SE & Co. KGaA pays a meaningful dividend of 3.04%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Fresenius SE & Co. KGaA does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Fresenius SE & Co. KGaA is 18.39%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Fresenius SE & Co. KGaA will have a dividend payout ratio of 13.68% next year. This indicates that Fresenius SE & Co. KGaA will be able to sustain or increase its dividend.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for FSNUY.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Fresenius SE & Co. KGaA this week, compared to 1 article on an average week.
MarketBeat Follows
Only 1 people have added Fresenius SE & Co. KGaA to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

N/A

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Fresenius SE & Co. KGaA insiders have not sold or bought any company stock.

3.8

Earnings and Valuation

Earnings Growth
Earnings for Fresenius SE & Co. KGaA are expected to grow by 21.88% in the coming year, from $0.96 to $1.17 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Fresenius SE & Co. KGaA is 6.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 112.58.
Price to Earnings Ratio vs. Sector
The P/E ratio of Fresenius SE & Co. KGaA is 6.15, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 77.69.
Price to Book Value per Share Ratio
Fresenius SE & Co. KGaA has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Stock

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Receive FSNUY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fresenius SE & Co. KGaA and its competitors with MarketBeat's FREE daily newsletter.

FSNUY Stock News Headlines

September 22, 2022 | americanbankingnews.com

Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) Receives $46.82 Consensus Target Price from Brokerages

September 6, 2022 | benzinga.com

Fresenius Kabi Receives U.S. FDA Approval for Biosimilar Stimufend® (pegfilgrastim - fpgk)

August 26, 2022 | nasdaq.com

Partial sale of Fresenius' Helios could be halted - WirtschaftsWoche

August 19, 2022 | uk.finance.yahoo.com

Michael Sen to become new CEO of Fresenius SE

August 19, 2022 | marketwatch.com

Fresenius CEO to Leave Company; Fresenius Kabi Chief to Take Over

August 12, 2022 | bizjournals.com

Fresenius Kidney Care center sold to California-based group

August 5, 2022 | seekingalpha.com

Fresenius SE & Co. KGaA 2022 Q2 - Results - Earnings Call Presentation

August 3, 2022 | nasdaq.com

Fresenius Medical Care Q2 Adj. Profit Flat YoY

August 1, 2022 | markets.businessinsider.com

Fresenius Medical Care earnings: here's what to expect

July 28, 2022 | msn.com

German health care company Fresenius cuts outlook for fiscal 2022

July 28, 2022 | msn.com

Fresenius Shares Slide as Group Issues Full-Year Profit Warning

July 28, 2022 | finance.yahoo.com

Fresenius Medical shares at 12-yr low as labour costs weigh on profit

July 27, 2022 | uk.finance.yahoo.com

Fresenius aims to merge Helios with competitor to boost growth - report

July 19, 2022 | finance.yahoo.com

After Plunging 11.8% in 4 Weeks, Here's Why the Trend Might Reverse for Fresenius (FMS)

July 18, 2022 | nz.finance.yahoo.com

Fresenius Kabi Introduces Generic Iodixanol Contrast Media Agent

July 14, 2022 | seekingalpha.com

Fresenius slips as U.S. joins whistleblower lawsuit over Medicare fraud

July 10, 2022 | finance.yahoo.com

Musk’s About-Face on Twitter Shifts Takeover Saga to Delaware

June 19, 2022 | seekingalpha.com

Fresenius: Revisiting The Thesis - Still A Buy

June 4, 2022 | uk.finance.yahoo.com

Fresenius plans to cut 2,000 jobs globally at Kabi unit - Handelsblatt

May 5, 2022 | seekingalpha.com

Fresenius SE & Co. KGaA 2022 Q1 - Results - Earnings Call Presentation

May 4, 2022 | apnews.com

Fresenius: Q1 Earnings Snapshot

May 3, 2022 | nasdaq.com

Fresenius Medical Care names new CEO as of Jan. 1

May 2, 2022 | finance.yahoo.com

Fresenius Kabi Introduces New Generic for the Treatment of Multiple Myeloma

April 27, 2022 | finance.yahoo.com

Fresenius Kabi Introduces Calcium Gluconate in Sodium Chloride Injection in Ready-to-Administer freeflex® Bags

April 14, 2022 | seekingalpha.com

Fresenius: Undervalued Healthcare Giant

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive FSNUY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fresenius SE & Co. KGaA and its competitors with MarketBeat's FREE daily newsletter.

FSNUY Company Calendar

Last Earnings: 8/02/2022
Today: 9/27/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:FSNUY
CUSIP: N/A
CIK: N/A
Web: www.fresenius.com
Phone: (496) 172-6080
Fax: N/A
Employees: 316,078
Year Founded: 1912

Price Target and Rating

Average Stock Price Forecast: $46.82
High Stock Price Forecast: $87.00
Low Stock Price Forecast: $26.00
Forecasted Upside/Downside: +775.2%
Consensus Rating: Hold
Rating Score (0-4): 2.44
Research Coverage: 9 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.87
Trailing P/E Ratio: 6.15
Forward P/E Ratio: 5.57
P/E Growth: N/A
Net Income: $2.15 billion
Net Margins: 4.39%
Pretax Margin: 8.74%
Return on Equity: 6.18%
Return on Assets: 2.54%

Debt

Debt-to-Equity Ratio: 0.58
Current Ratio: 1.32
Quick Ratio: 0.99

Sales & Book Value

Annual Sales: $44.39 billion
Price / Sales: 0.27
Cash Flow: $2.41 per share
Price / Cash Flow: 2.22
Book Value: $15.51 per share
Price / Book: 0.34

Miscellaneous

Outstanding Shares: 2,252,950,000
Free Float: N/A
Market Cap: $12.05 billion
Optionable: Not Optionable
Beta: 1.10

Social Links

Key Executives

Mr. Stephan Sturm (Age 59)
CEO, Pres & Chairman of Management Board - Fresenius Management SE
Comp: $3.74M

Dr. Francesco De Meo (Age 59)
Member of Management Board - Fresenius Management SE
Comp: $2.31M

Dr. Ernst Wastler (Age 64)
Member of Management Board - Fresenius Management SE
Comp: $1.77M

Mr. Rice Powell (Age 67)
Member of Management Board - Fresenius Management SE
Comp: $3.75M

Dr. Sebastian Biedenkopf (Age 58)
Chief Legal Officer, HR, Labor Relations Director, Risk Mgmt & Member of Mgmt. Board
Comp: $1.48M

Mr. Michael Sen (Age 54)
Member of Management Board - Fresenius Management SE
Comp: $2.19M

Ms. Sara Hennicken (Age 42)
Chief Financial Officer

Mr. Markus Georgi
Sr. VP of Investor Relations

Matthias Link
Sr. VP Corp. Communications

Key Competitors

View All Competitors

FSNUY Stock - Frequently Asked Questions

Should I buy or sell Fresenius SE & Co. KGaA stock right now?: 9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fresenius SE & Co. KGaA in the last year. There are currently 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" FSNUY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FSNUY, but not buy additional shares or sell existing shares.
View FSNUY analyst ratings or view top-rated stocks.
What is Fresenius SE & Co. KGaA's stock price forecast for 2022?: 9 brokers have issued 12-month target prices for Fresenius SE & Co. KGaA's shares. Their FSNUY share price forecasts range from $26.00 to $87.00. On average, they anticipate the company's share price to reach $46.82 in the next twelve months. This suggests a possible upside of 775.2% from the stock's current price.
View analysts price targets for FSNUY or view top-rated stocks among Wall Street analysts.
How have FSNUY shares performed in 2022?: Fresenius SE & Co. KGaA's stock was trading at $9.98 on January 1st, 2022. Since then, FSNUY stock has decreased by 46.4% and is now trading at $5.35.
View the best growth stocks for 2022 here.
Are investors shorting Fresenius SE & Co. KGaA?: Fresenius SE & Co. KGaA saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 198,300 shares, an increase of 642.7% from the August 15th total of 26,700 shares. Based on an average daily volume of 565,600 shares, the days-to-cover ratio is currently 0.4 days.
View Fresenius SE & Co. KGaA's Short Interest.
How were Fresenius SE & Co. KGaA's earnings last quarter?: Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) posted its earnings results on Tuesday, August, 2nd. The company reported $0.21 EPS for the quarter. The firm earned $10.67 billion during the quarter. Fresenius SE & Co. KGaA had a net margin of 4.39% and a trailing twelve-month return on equity of 6.18%.

Is Fresenius SE & Co. KGaA a good dividend stock?: Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) pays an annual dividend of $0.16 per share and currently has a dividend yield of 3.04%. The dividend payout ratio is 18.39%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, FSNUY will have a dividend payout ratio of 13.68% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for FSNUY.
What is Fresenius SE & Co. KGaA's stock symbol?: Fresenius SE & Co. KGaA trades on the OTCMKTS under the ticker symbol "FSNUY."
How do I buy shares of Fresenius SE & Co. KGaA?: Shares of FSNUY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Fresenius SE & Co. KGaA's stock price today?: One share of FSNUY stock can currently be purchased for approximately $5.35.
How much money does Fresenius SE & Co. KGaA make?: Fresenius SE & Co. KGaA (OTCMKTS:FSNUY) has a market capitalization of $12.05 billion and generates $44.39 billion in revenue each year. The company earns $2.15 billion in net income (profit) each year or $0.87 on an earnings per share basis.
How many employees does Fresenius SE & Co. KGaA have?: The company employs 316,078 workers across the globe.
How can I contact Fresenius SE & Co. KGaA?: Fresenius SE & Co. KGaA's mailing address is Else-Kroner-Strasse 1, Bad Homburg 2M, 61352. The official website for the company is www.fresenius.com. The company can be reached via phone at (496) 172-6080 or via email at ir-fre@fresenius.com.

This page (OTCMKTS:FSNUY) was last updated on 9/27/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Fresenius SE & Co. KGaA - FSNUY Stock Forecast, Price & News

Fresenius SE & Co. KGaA MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month